Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing POINT Biopharma's SPLASH study results of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC)

Ticker(s): PNT

Who's the expert?

Institution: Weill Cornell Medicine

Medical Director of the Genitourinary Oncology Research Program and WCMC principal investigator for the Alliance for Clinical Trials in Oncology.
Currently manages 200 patients with prostate cancer
Author on the paper: "Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer as a predictive biomarker for targeted therapy"

Interview Goal

This conversation will focus on the results from PNT's SPLASH study: "Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC) with a PI.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.